["{\"step_by_step_thinking\": \"The relevant documents do not mention the approved dose of misoprostol in emergent management of postpaum hemorrhage. The documents discuss the use of misoprostol for prevention of nonsteroidal anti-inflammatory drug-induced gastropathy, as well as its efficacy in treating NSAID-induced mucosal lesions. However, they do not provide information on the approved dose of misoprostol for this specific indication.\", \"answer_choice\": \"D\" (None of the above)}"]